Author Archives | DavidRobinson
DavidRobinson - who has written 16 posts on FavStocks.
Dave Robinson mainly focuses his research on various aspects of corporate finance and financial reporting. He tracks how stock prices respond to new earning releases, for companies in a wide variety of sectors.
Dave also enjoys looking for companies in currently unpopular industries, experiencing a short term setbacks in earnings, or spinoffs and asset sales, into newly created companies, and he aims to find these before they are discovered by the majority of other investors
He received his MBA in Accounting and Finance from University of Houston.
Taro Announces T2007 Clinical Trials (OTC:TAROF)
Taro Pharmaceutical Industries Ltd (OTC:TAROF) has announced that they have begun the Phase 1 of clinical trials in Canada with T2007 which is second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.
Continue reading...Enzo Biochem Signs Marketing Agreement (NYSE:ENZ)
15 December 2009
Comments Off
Enzo Biochem Inc (NYSE:ENZ) has announced that they have signed an exclusive marketing deal with privately owned Ikonisys Inc of New Haven, CT.
Continue reading...Quidel’s Stock Repurchase Program (NASDAQ:QDEL)
9 December 2009
Comments Off
Quidel Corporation (NASDAQ:QDEL) has announced that their Board of Directors have authorized for an extension of the Company’s current common stock repurchase program.
Continue reading...Depomed Receives Certification Notice (NASDAQ:DEPO)
11 November 2009
Comments Off
Depomed, Inc (NASDAQ:DEPO) announced that they have received a Paragraph IV certification notice from Lupin Limited advising Depomed of the filing of an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration for a generic version of GLUMETZA (metformin hydrochloride extended release tablet) of 500 mg and 1000 mg strengths.
Continue reading...NovaDel’s USPTO Allowance Notice (AMEX:NVD)
6 November 2009
Comments Off
NovaDel Pharma Inc. (AMEX:NVD) announced that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715 entitled “Buccal, Polar and Non-Polar Spray containing Zolpidem†that covers a method of treating insomnia by administering zolpidem to human beings utilizing NovaMist Oral Spray [...]
Continue reading...Pro-Pharmaceuticals Private Placement (OTC:PRWP)
5 November 2009
Comments Off
Pro-Pharmaceuticals, Inc. (OTC:PRWP) has announced that they have closed a US$310,000 tranche of a private placement for up to US$6.0 million with 10X Fund, L.P. which is purchasing their unregistered Series B convertible preferred stocks and warrants.
Continue reading...Depomed Q3 Financial Results (NASDAQ:DEPO)
30 October 2009
Comments Off
Depomed, Inc (NASDAQ:DEPO) today reported financial results for the third quarter that ended on September 30, 2009.
Continue reading...Whirlpool profit higher than expected (NYSE:WHR)
23 October 2009
Comments Off
Whirlpool Corporation (NYSE:WHR) reported a higher than expected quarterly profit as cost cuts offset weak sales.
Continue reading...Honeywell Profits Slides (NYSE:HON)
23 October 2009
Comments Off
Honeywell International Inc. (NYSE:HON) announced that they have lowered their 2009 revenue guidance as they have reported a slide of 15 percent in their third quarter earnings.
Continue reading...OxiGENE’s New Merger (NASDAQ:OXGN)
16 October 2009
Comments Off
OxiGENE and VaxGen on Thursday morning announced that they have entered into a definitive merger agreement where OxiGENE will acquire VaxGen in exchange for common stock of OxiGENE Inc.
Continue reading...
23 December 2009
Comments Off